Company: BIAF
Filing Date: 2025-04-22
Form Type: 424B3
Source: 0001641172-25-005598
Chunk: 152

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-22
Form: 424B3
Chunk 152
---
     
 as Chief Financial Officer of the Company, effective November 5, 2024.                                                                     |
| (6) | Includes                                                                                                                                   
 for 2024 the following amounts received by Mr. Girgenti for his service to the Company as a director: (i) in the Salary column —           
 $35,000, and (ii) in the Stock Awards column — $148,377.                                                                                   |

| 71 |

Narrative Disclosure to Summary Compensation Table

Base Salaries

The Company uses base salaries to recognize the experience, skills, knowledge, and responsibilities required of all its employees, including the NEOs. Base salaries are reviewed annually and adjusted from time to time to realign salaries with market levels after taking into account individual responsibilities, performance, and experience. For 2024, the annual base salaries of the Company’s NEOs were:

| ● | For                                                                                                                                  
 Ms. Zannes: $260,000 through October 31, 2024 and $300,000 commencing November 1, 2024 (which amounts do not include $25,000 in fees 
 paid to Ms. Zannes for her service as a director in 2024);                                                                           |
| ● | For                                                                                                                                  
 Mr. Edwards: $300,000(1); and                                                                                                        |
| ● | For                                                                                                                                  
 Mr. Girgenti: $120,000 (which amount does not include $35,000 in fees paid to Mr. Girgenti for his service as a director in 2024).   |

| (1) | Mr.                                                                                                                                   
 Edwards’ employment agreement provides that he will receive an annual base salary of $300,000. Mr. Edwards was employed pursuant      
 to such agreement as of November 5, 2024, accordingly, he received a pro-rated portion of such salary in 2024. In addition, he served 
 as a consultant to Company from September 16, 2024 through October 31, 2024 for which he was paid consulting fees of $31,438.         |

Bonuses

On January 26, 2024, the Compensation Committee adopted the bioAffinity Technologies, Inc. Management Incentive Bonus Plan. The purpose of the Bonus Plan is to align officers’ and other employees’ efforts with the strategic goals of the Company through competitive annual incentive opportunities. The Bonus Plan is administered by the Compensation Committee. The Compensation Committee has the power to grant awards under the Bonus Plan, determine the amount of cash and/or equity